3-bromo-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methylpyridine | 1541125-83-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-bromo-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methylpyridine
• 英文别名: 3-Bromo-6-(2,5-dimethyl-pyrrol-1-yl)-2-methyl-pyridine；3-bromo-6-(2,5-dimethylpyrrol-1-yl)-2-methylpyridine
• CAS: 1541125-83-0
• 化学式: C₁₂H₁₃BrN₂
• 分子量: 265.153
• InChiKey: HKOCIJIZJPCWCT-UHFFFAOYSA-N

物化性质

• 沸点：
  342.9±42.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-bromo-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methylpyridine 在 四(三苯基膦)钯 、 正丁基锂 、 三乙胺 、 二异丙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 25.0h， 生成 (E)-ethyl 3-(6-(2,5-dimethyl-1H-pyrrol-1-yl)-4-(isopropylamino)-2-methylpyridin-3-yl)acrylate
  参考文献：
  名称：

  Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors

  摘要：

  Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin ( mTOR) signaling pathway is one of the most intensively studied approaches to cancer therapy. Rational design led to the identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. Design, synthesis and structure activity relationship are reported. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.112
• 作为产物：
  描述：

  2-氨基-5-溴-6-甲基吡啶 、 2,5-己二酮 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 以77 %的产率得到3-bromo-6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methylpyridine
  参考文献：
  名称：

  [EN] DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
  [FR] DÉGRADATION DE LA TYROSINE KINASE DE BRUTON (BTK) PAR CONJUGAISON D'INHIBITEURS DE BTK AVEC UN LIGAND DE LIGASE E3 ET PROCÉDÉS D'UTILISATION

  摘要：

  Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.

  公开号：

  WO2023125908A1

文献信息

• [EN] DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE<br/>[FR] DÉGRADATION DE LA TYROSINE KINASE DE BRUTON (BTK) PAR CONJUGAISON D'INHIBITEURS DE BTK AVEC UN LIGAND DE LIGASE E3 ET PROCÉDÉS D'UTILISATION
  申请人：[en]BEIGENE, LTD.

  公开号：WO2023125908A1

  公开（公告）日：2023-07-06

  Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
• Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors
  作者：Songwen Lin、Fangbin Han、Peng Liu、Jing Tao、Xuechao Zhong、Xiujie Liu、Chongqin Yi、Heng Xu

  DOI：10.1016/j.bmcl.2013.12.112

  日期：2014.2

  Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin ( mTOR) signaling pathway is one of the most intensively studied approaches to cancer therapy. Rational design led to the identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. Design, synthesis and structure activity relationship are reported. (C) 2013 Elsevier Ltd. All rights reserved.